The worst pharma launch of all time?
Biogen’s Alzheimer’s disease drug Aduhelm has seen slow uptake from the get-go, hampered by inconclusive efficacy data and a $56,000 sticker price. The firm’s third-quarter earnings reveal just how slow its debut has been.
Aduhelm rang in sales of only $300,000 in the first full quarter since the drug was approved in June, short of the $12 million forecast by Wall Street. That spurred analysts at Raymond James to call it “potentially the worst drug launch of all time” given “persistent hyperbole about the drug’s purported benefits,” in a note to investors Wednesday.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
